US Pharm. 2007;32(11):52-58.
Borderline personality disorder
(BPD) is a psychiatric condition in which patients display a "pervasive
pattern of instability of interpersonal relationships, self-image, affects,
and marked impulsivity that begins by early adulthood and is present in a
variety of contexts."1 It is a severe and often chronic
psychiatric condition causing limitations in patients' social and occupational
functioning. BPD is the most common personality disorder, with an estimated
prevalence of 1% to 2% in the general population, of 10% in outpatients
receiving mental health care, and of 20% in inpatients in psychiatric
facilities.1-3 Among patients clinically treated for personality
disorders, 30% to 60% have been identified as having BPD. This disorder is
largely diagnosed in women, with an estimated female to male ratio of 3:1;
however, some studies have contradicted this and demonstrated similar
prevalence between males and females.3
The prognosis for patients
with BPD is variable but generally better than for those with other
psychiatric conditions.4 Two-hundred and ninety patients with BPD
participated in a study to determine what baseline predictors were most
relevant regarding time to remission. Patients were evaluated every two years
for a total of 10 years to ascertain if they still met the diagnostic criteria
for BPD. Eighty-eight percent of 275 patients who were reassessed at least
once during the 10-year follow-up achieved remission. Sixty-two percent of
patients achieved remission by four years.5 Factors that favor a
better long-term outcome include a high IQ, being unusually talented or
physically attractive, the absence of parental divorce and narcissistic
entitlement, and the presence of physically self-destructive acts during the
index admission. Factors associated with a poorer long-term outcome include
affective instability, chronic dysphoria, younger age at first treatment,
increased length of prior hospitalization, antisocial behavior, substance
abuse, parental brutality, family history of psychiatric illness, a
problematic relationship with one's mother, and the presence of maternal
psychopathology.4,5
Etiology and Pathophysiology
The etiology of BPD is
multifactorial in nature and can be broken down into genetic, neurobiological,
and psychosocial components. Genetics is thought to be a large part of BPD,
although specific genetic factors have not been fully elicited. Individuals
with first-degree relatives who suffer from BPD are five times more likely to
inherit the disorder than individuals in the general population.1 A
Norwegian twin study of 92 monozygotic and 129 dizygotic pairs demonstrated
concordance rates for BPD of 35% and 7%, respectively.6
Multivariate genetic analyses identified four genetic factors found in
patients with BPD. The factors and their prevalence are emotional
dysregulation (47%), dissocial behavior (50%), inhibitedness (48%), and
compulsivity (38%).6
There is also evidence to
support the neurobiological aspects of the disorder. It has been reported that
impulsive aggression is a result of reduced serotonergic activity in the
orbital and medial prefrontal cortex, while the noradrenergic system may
contribute to the affective instability of patients with BPD.6
Increased dopaminergic activity has also been reported to be associated with
some of the "mini psychotic episodes" displayed in borderline patients.
6 These possible mechanisms explain why certain classes of medication
are utilized to treat BPD
Environmental factors are
thought to be the major contributor in the psychosocial component of BPD. Many
borderline patients have a history of childhood trauma such as sexual or
physical abuse.6 Childhood sexual abuse is reported in 40% to 70%
of inpatients with BPD.5 Researchers have suggested that this early
trauma may reset the hypothalamo-pituitary-adreno (HPA) axis, normally
utilized by the body to manage stress.6 Further research is needed
to fully understand the etiology of BPD and the role of various components.
Diagnosis and Clinical
Presentation
The diagnostic
criteria from the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR) are listed in TABLE 1. A patient must display at least
five of the nine criteria for a diagnosis. These behaviors should represent a
pattern appearing by early adulthood. TABLE 2 lists examples of
symptoms that fit into three behavioral dimensions of BPD. The dimensions are
affective dysregulation, impulsive-behavioral dyscontrol, and
cognitive-perceptual symptoms.2
Patients with BPD have a severe fear
of abandonment, which frequently leads to unrealistic accusations, displaying
inappropriate anger, self-mutilation, and making impulsive decisions.
Relationships with others tend to be unstable, and "splitting" commonly occurs
where people or situations in their lives are viewed as all good or all
bad, right or wrong. Patients may have identity disturbances and see
themselves as evil or maybe not existing at all. They may quickly trade their
own values and beliefs for another individual's. Chronic self-destructive
behavior is common in these patients. This includes attempted and completed
suicide, self-mutilation, unsafe sexual promiscuity, substance abuse, reckless
driving, gambling, spending sprees, or binge eating. Approximately 8% to 10%
of borderline patients commit suicide, with many more attempting suicide
sometime in their life.1,2 Occasionally, at times of high stress,
borderline patients may have transient psychotic-like symptoms lasting for
minutes to hours.2
The most common clinical
comorbidities associated with BPD are mood disorders, substance-related
disorders, eating disorders (especially bulimia), posttraumatic stress
disorder, panic disorder, and attention-deficit hyperactivity disorder (ADHD),
as well as other personality disorders.1,2
Treatment
Treatment options
for BPD include psychotherapy and pharmacotherapy. One evidence-based form of
psychotherapy is dialectical behavior therapy (DBT). This consists of weekly
one-hour individual sessions with a therapist for a year and weekly 2.5-hour
sessions of group skills training for six to 12 months. DBT has been shown to
decrease parasuicidal behavior and psychiatric hospital admissions as well as
improve symptoms of depression and anger.2 Other psychotherapies,
such as comprehensive validation therapy (CVT), interpersonal therapy,
cognitive therapy, cognitive analytic therapy (CAT), a combination of
cognitive and psychodynamic therapy, and systems training for emotional
predictability and problem solving (STEPPS), are being evaluated in clinical
trials.2,3
Pharmacologic therapies do not
cure this disorder; instead, they are used to treat the symptoms associated
with the behavioral dimensions of BPD.2 No agents are currently
approved by the FDA for the treatment of BPD; however, medications that have
been used include selective serotonin reuptake inhibitors (SSRIs), tricyclic
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), antipsychotics
(typical and atypical), mood stabilizers, benzodiazepines (BZDs), naltrexone,
and ethyl-eicosapentaenoic acid (E-EPA), an omega-3 fatty acid. There is
little research comparing psychotherapy and pharmacotherapy. For this reason,
a combination of psychotherapy and pharmacotherapy is recommended.
Pharmacotherapy
Antidepressants: Much
of the data supporting the use of antidepressants in the treatment of
borderline personality disorder is from the American Psychiatric Association
guidelines developed in 2001. The treatment guidelines identify several small,
open-label studies using fluoxetine, sertraline, and venlafaxine for symptoms
such as aggression, irritability, depressed mood, and self-mutilation.2
Three randomized, double-blind, placebo-controlled trials of fluoxetine
mentioned in the guidelines also showed significant improvement in depressed
mood, anger, anxiety, aggression, and global functioning.2 There is
limited evidence of SSRI efficacy, however, in more recent randomized
controlled trials. Rinne et al. conducted a double-blind, 24-week, randomized
trial of fluvoxamine in female patients.7 Subjects were randomized
to either fluvoxamine or placebo for six weeks followed by a blind half
crossover to fluvoxamine for those who were on placebo. Fluvoxamine was found
to have a statistically significant effect on the occurrence of rapid mood
shifts independent of coexisting PTSD or depression; however, no effects on
anger and impulsivity were seen.7 In another randomized,
double-blind trial, DBT plus placebo and DBT plus fluoxetine were compared.
8 The fluoxetine group was not found to improve symptoms of anger,
depression, anxiety, or global symptoms over the placebo group. Zanarini et
al. randomized women with BPD but without comorbid major depressive disorder
to fluoxetine, olanzapine, or a combination of both.9 Fluoxetine
was the least effective treatment for aggression and depressive symptoms
compared to olanzapine and the combination.
TCAs have also been used in
borderline patients for depressed mood, irritability, and mood lability.
Amitriptyline, imipramine, and desipramine have been studied in double-blind,
placebo-controlled trials in patients with BPD.2 In a double-blind,
placebo-controlled trial of amitriptyline and haloperidol, amitriptyline
responders improved in global functioning, depression, psychoticism, and
impulsive behavior, but not in self-rated hostility.10
Nonresponders, however, had paradoxical effects demonstrated by progressive
worsening in global functioning, paranoid ideation, and impulsive behavior.
10 TCAs have a more unfavorable side-effect profile compared to SSRIs.
Patients taking this class of drugs often complain of sedation, constipation,
dry mouth, and weight gain. Also, borderline patients are at a greater risk
for suicide, and overdosing on a TCA is dangerous and potentially fatal. TCAs
are not viable options for patients with cardiac abnormalities since they can
induce tachycardia and arrhythmias. The usefullness of TCAs to treat comorbid
depression or other symptoms of affective dysregulation is ambiguous at best.
2
MAOIs are known to improve
mood-related symptoms such as depression, hostility, and impulsivity in
borderline patients.2 Phenelzine showed global improvement in 92%
of outpatients with atypical depression and BPD as a comorbid disorder
compared to imipramine.11 In another double-blind,
placebo-controlled, crossover trial of alprazolam, carbamazepine,
trifluoperazine, and tranylcypromine, both physician and patient ratings
decreased for depression, anger, and rejection sensitivity in the patients
using tranylcypromine. Impulsivity and suicidality also decreased in these
patients while capacity for pleasure increased. Finally, an effect on behavior
dyscontrol trended toward significance.12 Although studies have
shown the benefit of using MOAIs for BPD, this drug class may not be the
safest choice of medication. MAOIs have dangerous drug interactions, such as
serotonin syndrome and hypertensive crises, with multiple medications, many of
which are found OTC. Patients taking MAOIs must implement strict dietary
restrictions to foods containing tyramine, also linked with hypertensive
crises.2
Despite a lack of recent
evidence, SSRIs have better side-effect profiles than other antidepressant
classes and fewer drug interactions, and they are relatively safe in overdose
situations. For this reason, SSRIs are recommended before the use of TCAs and
MAOIs.2
Mood Stabilizers:
The guidelines report
the results of a trial of lithium in patients with emotionally unstable
character disorder, a DSM-I diagnosis prior to BPD. Lithium decreased
variations in mood and increased global improvement. Further case reports in
borderline patients demonstrate that lithium has mood-stabilizing and
antiaggressive effects. In a double-blind, placebo-controlled crossover trial
of lithium and desipramine, therapist ratings of impulsivity decreased with
use of lithium compared to placebo.2 There are no other known
published trials of lithium since publication of the guidelines in 2001;
however, lithium appears to be useful for mood stabilization and aggression in
BPD.
Divalproex sodium or valproic
acid (VPA) has been shown to decrease symptoms of behavior dyscontrol and
affective dysregulation in small, open-label studies.2 The first
double-blind, placebo-controlled trial of VPA in BPD without bipolar disorder
examined effects on global improvement and functioning, depression,
aggression, irritability, and suicidality, all of which were not statistically
significant. The authors suggest that this may be due to a small sample size
and high drop-out rate.13 Frankenburg et al. conducted a
double-blind, placebo-controlled trial of VPA in borderline patients with
bipolar II disorder.14 Significant decreases in interpersonal
sensitivity, irritability, anger, hostility, and impulsive aggressiveness were
noted compared to placebo, but no effects were found on depression.14
In patients with higher baseline trait impulsivity and state aggression
symptoms, VPA-treated patients responded significantly better than
placebo-treated patients.15 Evidence suggests that VPA may be a
good option for treatment of patients with impulsive aggression and mood
variations.
Carbamazepine has been studied
in two double-blind, placebo-controlled trials with different results. The
first trial included patients with BPD, comorbid hysteroid dysphoria, and a
significant history of behavioral dyscontrol. Compared to placebo,
carbamazepine decreased the frequency and severity of behavioral dyscontrol
and improved anxiety, anger, and euphoria. The second trial included patients
with BPD but no other major psychiatric disorders. No significant differences
in behavior, impulsivity, or global improvement were found from placebo.2
An open-label study of oxcarbazepine in BPD showed improvement in global
functioning, anxiety, interpersonal relationships, impulsivity, affective
instability, and outbursts of anger. Scores for depression, abandonment,
identity, parasuicidal behavior, emptiness, dissociation, and paranoid
ideation were not significantly changed.16
Lamotrigine may be a new and
promising therapy to treat patients with BPD. Impulsive sexual, drug-taking,
and suicidal behaviors decreased in lamotrigine responders in an open-case
series of patients who had failed other therapies.17 An eight-week,
double-blind, placebo-controlled trial of female patients with BPD and
aggression showed significant decreases in anger outbursts and increased
ability to control anger overall.18 Lamotrigine is not currently
recommended in the guidelines, and, until more clinical studies prove benefit,
it should be saved for patients who have failed other medications.
Topiramate may also be a
viable treatment option for BPD. Two double-blind, placebo-controlled
trials--one in males and the other in females--demonstrated decreased intensity
and readiness to react to anger in patients taking topiramate. A decrease in
anger outbursts and increased ability to control anger were also noted.
19,20 Loew et al. compared topiramate to placebo in a double-blind,
placebo-controlled trial.21 Compared to placebo, a significant
change in somatization, interpersonal sensitivity, anxiety, hostility, phobic
anxiety, and severity of mental stress was noted. There was no change in
obsessive–compulsiveness, depression, paranoid ideation, or psychoticism.
Topiramate also improved health-related quality of life.21 Until
more clinical data are revealed, topiramate should also be used after other
therapies have failed.
Lithium and anticonvulsant
medications have shown effectiveness in treating symptoms of BPD such as mood
swings and improvement in aggression and impulsivity; however, they are not
effective for borderline patients with depressive symptoms.
Antipsychotics:
Typical and atypical
antipsychotic medications are frequently used to treat schizotypal and
psychotic symptoms as well as anger and hostility in patients with BPD.2
Typical antipsychotics studied
in clinical trials include thioridazine, haloperidol, perphenazine,
thiothixene, loxapine, and trifluoperazine.2 Studies using these
medications demonstrate improvement in affective and impulsive behavioral
symptoms; however, double-blind, placebo-controlled trials of haloperidol have
some conflicting evidence in effectiveness. In one study, haloperidol
increased global improvement, self- and observer-rated depression, anger,
hostility, schizotypal symptoms, psychoticism, and impulsivity in acutely ill
inpatients compared to placebo. However, another study done by the same
authors in less severe patients showed a difference only in hostility,
impulsivity, and aggression. Another study of haloperidol found worsened
depressive symptoms and improved irritability but no significant effect on
hostility.2
Clozapine, the first atypical
antipsychotic, has shown improvement in positive and negative psychotic
symptoms and global functioning in borderline patients with comorbid major
psychotic disorders. Researchers of these studies, however, are unsure if the
psychotic symptoms stem from BPD. In a study of clozapine in which all
patients with comorbid major psychotic disorders were excluded, clozapine
improved cognitive-perceptual, affective, and impulsive-behavior symptoms,
proving its effectiveness.2 A limitation to clozapine use is the
monitoring required by the Clozaril National Registry (CNR) due to the risk of
agranulocytosis.
More recently, other atypical
antipsychotics have been used because of the decreased risk of extrapyramidal
side effects (EPS). Open-label studies of ziprasidone, risperidone, and
quetiapine demonstrate improved global functioning and decreased symptoms of
depression, anxiety, and aggression. Mixed results were found with improvement
of psychotic symptoms.22-25 As described above, a double-blind
study of olanzapine, fluoxetine, and their combination was performed. The
combination was better for symptoms of aggression compared to either drug
alone; however, olanzapine improved depressive symptoms better than the
combination or fluoxetine.9 Olanzapine significantly improved
interpersonal sensitivity, anxiety, anger and hostility, and paranoia in a
double-blind, placebo-controlled trial of female patients with BPD, although
depression was unchanged.26 In another double-blind,
placebo-controlled study of olanzapine or placebo combined with DBT, the
olanzapine-treated group had greater improvement in depressive symptoms,
anxiety, and impulsive-aggressive behavior compared to placebo.27
Contradictory to these studies, Bogenschutz and Nurnberg found significant
improvement in global functioning but did not find any difference in anger,
aggression, anxiety, or depressive symptoms.28 They theorize that
this may be secondary to a lack of power to show a difference. Aripiprazole
has also been studied in a double-blind, placebo-controlled trial of
borderline patients. While obsessive-compulsiveness, insecurity in social
contacts, depression, anxiety, paranoid thinking, psychotic symptoms, and
anger all improved, aripiprazole did not improve somatization.29
The aripiprazole- and placebo-treated patients from this study were followed
in an 18-month open-label trial, and the results from the previous trial
persisted.30
Although evidence exists for
the use of typical antipsychotics, EPS and sedation limit their use. Atypical
antipsychotics offer similar efficacy with fewer side effects and should be
used before typical antipsychotics, although long-term metabolic complications
should be considered before instituting their use.
Other Therapies:
BZDs are widely used as
anxiolytics in patients with BPD. In a double-blind, placebo-controlled,
crossover study of outpatients with BPD, hysteroid dysphoria, and behavioral
dyscontrol, alprazolam was associated with increased suicidality and behavior
dyscontrol.2 Case reports of clonazepam as adjunctive therapy have
shown beneficial effects.2 BZDs have limited therapeutic evidence
and therefore should not be used as monotherapy for symptom management of BPD.
Opiate antagonists, such as
naloxone, have shown some benefit in case reports of borderline patients who
self-mutilate. The suggested mechanism behind their use is the blockade of
mutilation-induced analgesia or euphoria, thereby reducing self-injurious
behavior. Lack of evidence suggests this strategy should not be used routinely.
2
A double-blind,
placebo-controlled study using 1 g of E-EPA in female borderline patients was
published in 2003. Results showed that E-EPA–treated patients had significant
reductions in aggression and depressive symptoms.31 There are no
other clinical trials to validate the results, but future studies may prove
E-EPA beneficial for treatment of patients with BPD.
Summary
Treatment of BPD is
complex and at times extremely challenging. A combination of psychotherapy and
symptom-based pharmacotherapy is the most effective and comprehensive
treatment for patients. Pharmacotherapy has been used to treat symptoms of
affective dysregulation, impulsive-behavioral dyscontrol, and
cognitive-perceptual disturbances. Treatment options include SSRIs, TCAs,
MAOIs, lithium, anticonvulsant mood stabilizers, typical and atypical
antipsychotics, BZDs, opiate antagonists, and omega-3 fatty acids. SSRIs are
first-line treatment for symptoms of affective dysregulation and
impulsive-behavioral dyscontrol. Second- or third-line therapies are TCAs and
MAOIs. Antipsychotics are first-line treatment for cognitive-perceptual
disturbances. Most patients will require multiple medications, including
antidepressants, mood stabilizers, and antipsychotics to treat their variety
of symptoms.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC:
American Psychiatric Association; 2000:706-710.
2. Oldham JM, Gabbard GO, et al. Practice guideline for the treatment of
patients with borderline personality disorder. Am J Psychiatry.
2001;158(suppl 10):1-52.
3. Oldham, JM. Guideline Watch: Practice Guideline for the Treatment of
Patients with Borderline Personality Disorder. Arlington, VA: American
Psychiatric Association; 2005:1-9.
4. Lieb K, Zanarini MC, et al. Borderline personality disorder. Lancet.
2004;364:453-461.
5. Zanarini MC, Frankenburg FR, et al. Prediction of the 10-year course of
borderline personality disorder. Am J Psychiatry. 2006;163:827-832.
6. Skodol AE, Siever LJ, et al. The borderline diagnosis II: biology,
genetics, and clinical course. Biol Psychiatry. 2002;51:951-963.
7. Rinne T, van den Brink W, Wouters L, et al. SSRI treatment of borderline
personality disorder: a randomized, placebo-controlled clinical trial for
female patients with borderline personality disorder. Am J Psychiatry.
2002;159:2048-2054.
8. Simpson EB, Yen S, et al. Combined dialectical behavior therapy and
fluoxetine in the treatment of borderline personality disorder. J Clin
Psychiatry. 2004;65:379-385.
9. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial
of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women
with borderline personality disorder. J Clin Psychiatry. 2004;
65:903-907.
10. Soloff PH, George A, et al. Paradoxical effects of amitriptyline on
borderline patients. Am J Psychiatry. 1986;143:1603-1605.
11. Parsons B, Quitkin FM, et al. Phenelzine, imipramine, and placebo in
borderline patients meeting criteria for atypical depression.
Psychopharmacol Bull. 1989;25:524-534.
12. Cowdry RW, Gardner DL. Pharmacotherapy of borderine personality disorder:
alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen
Psychiatry. 1988;45:111-119.
13. Hollander E, Allen A, et al. A preliminary double-blind,
placebo-controlled trial of divalproex sodium in borderline personality
disorder. J Clin Psychiatry. 2001;62:199-203.
14. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with
borderline personality disorder and bipolar II disorder: a double-blind
placebo controlled pilot study. J Clin Psychiatry. 2002;63:442-446.
15. Hollander E, Swann AC, et al. Impact of trait impulsivity and state
aggression on divalproex versus placebo response in borderline personality
disorder. Am J Psychiatry. 2005;162:621-624.
16. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of
borderline personality disorder: a pilot study. J Clin Psychiatry.
2005;66:1111-1115.
17. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline
personality: an open case series without concurrent DSM-IV major mood
disorder. J Affect Disord. 1998;51:333-343.
18. Tritt K, Nickel C, et al. Lamotrigine treatment of aggression in female
borderline-patients: a randomized, double-blind, placebo-controlled study.
J Psychopharmacol. 2005;19:287-291.
19. Nickel MK, Nickel C, et al. Topiramate treatment of aggression in female
borderline personality disorder patients: a double-blind, placebo-controlled
study. J Clin Psychiatry. 2004;54:1515-1519.
20. Nickel MK, Nickel C, et al. Treatment of aggression with topiramate in
male borderline patients: a double-blind, placebo-controlled study. Biol
Psychiatry. 2005;57:495-499.
21. Loew TH, Nickel MK, et al. Topiramate treatment for women with borderline
personality disorder: a double-blind, placebo-controlled study. J Clin
Psychopharmacol. 2006;26:61-66.
22. Pascual JC, Oller S, et al. Ziprasidone in the acute treatment of
borderline personality disorder in psychiatric emergency services. J Clin
Psychiatry. 2004;65:1281-1283.
23. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline
personality disorder with risperidone. J Clin Psychiatry.
2002;63:241-244.
24. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic
quetiapine for treatment of borderline personality disorder: impulsivity as
main target. J Clin Psychiatry. 2005;66:1298-1303.
25. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine
in the treatment of borderline personality disorder: a pilot study. J Clin
Psychiatry. 2006;67:1042-1046.
26. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline
personality disorder patients: a double-blind, placebo-controlled pilot study.
J Clin Psychiatry. 2001;62:849-854.
27. Soler J, Pascual JC, et al. Double-blind, placebo-controlled study of
dialectical behavior therapy plus olanzapine for borderline personality
disorder. Am J Psychiatry. 2005;162:1221-1224.
28. Bogenschultz MP, Nurnberg HG. Olanzapine versus placebo in the treatment
of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
29. Nickel MK, Muehlbacher M, et al. Aripiprazole in the treatment of patients
with borderline personality disorder: a double-blind, placebo-controlled
study. Am J Psychiatry. 2006;163:833-838.
30. Nickel MK, Loew TH, Gil FP. Aripiprazole in treatment of borderline
patients, part II: an 18 month follow-up. Psychopharmacology.
2007;191:1023-1026.
31. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with
borderline personality disorder: a double-blind, placebo-controlled pilot
study. Am J Psychiatry. 2003; 160:167-169.
To comment on this article, contact editor@uspharmacist.com.